

---

## ExpreS<sup>2</sup>ion Biotech Holding AB approved for listing on Nasdaq Stockholm First North

ExpreS<sup>2</sup>ion Biotech Holding AB ("ExpreS<sup>2</sup>ion ") announces that the Company has met the requirements for listing on Nasdaq Stockholm First North and today, July 27, it has received the stock exchange's formal approval. The first day of trading of ExpreS<sup>2</sup>ion's shares is expected to be July 29, 2016.

### CEO Steen Klysner comments

*"In June we carried out a successful Initial Public Offering (IPO), which reflected the interest there is in ExpreS<sup>2</sup>ion. With the proceeds from the IPO, we can now continue to expand our marketing and sales efforts to enable a larger market penetration for our ExpreS<sup>2</sup> platform."*

### Company description available

ExpreS<sup>2</sup>ions company description is available via the following link:  
<http://www.expres2ionbio.com/files/bolagsbeskrivning.pdf>

### Financial Advisors and Certified Advisor

Sedermora Fondkommission is appointed as Certified Adviser for the Company.

### For further information about ExpreS<sup>2</sup>ion, please contact:

Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: [sk@expres2ionbio.com](mailto:sk@expres2ionbio.com)

*This press release contains information that ExpreS<sup>2</sup>ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20.15 CET, July the 27<sup>th</sup> 2016.*

---

### About ExpreS<sup>2</sup>ion

ExpreS<sup>2</sup>ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS<sup>2</sup>ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS<sup>2</sup> platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.